No canine rabies, no canine babies: Smaller exposure risks to both children and adults

November 20, 2013

(Philadelphia) - Thomas Jefferson University announced today that it is a Grand Challenges Explorations winner, an initiative funded by the Bill & Melinda Gates Foundation. Milosz Faber, Ph.D., an Assistant Professor in the department of Microbiology and Immunology will pursue an innovative global health and development research project, titled "Development of a single dose contraceptive rabies vaccine."

Rabies has become a seriously neglected disease in the developing world. It causes globally an estimated 70,000 human deaths and 15 million people, of which 40 percent are children, undergo rabies post-exposure prophylaxis each year. Domestic dogs, which are found in high densities in several continents and often associated with rabies, are responsible for more than 95percent of the human rabies cases world-wide. Therefore, the most effective way to control of human rabies would be the eradication of dog rabies. However, since most of the dogs in developing countries are free-ranging, elimination of dog rabies can only be achieved through a combination of vaccination and population control programs. The aim of this project is to develop a cost-effective and safe contraceptive rabies vaccine formulation that would accomplish both objectives with a single dose.

The vaccine will be based on recently developed non-pathogenic rabies variant TriGAS which targets dendritic cells and thereby strongly induces a strong and sustained immune response not only to rabies virus but also to foreign antigen such as gonadotropin-releasing hormone (GnRH). The novel vaccine formulation resulting from the studies on this project will induce, after a single inoculation, both long-term protective immunity against rabies and infertility without causing adverse effects.

Grand Challenges Explorations (GCE) funds individuals worldwide to explore ideas that can break the mold in how persistent global health and development challenges are solved. Dr. Faber's project is one of more than 80 Grand Challenges Explorations Round 11 grants announced today by the Bill & Melinda Gates Foundation.

To receive funding, Dr. Faber and other Grand Challenges Explorations Round 11 winners demonstrated in a two-page online application a bold idea in one of five critical global heath and development topic areas that included development of the next generation condom, agriculture development, and neglected tropical diseases.
-end-
About Grand Challenges Explorations

Grand Challenges Explorations is a US$100 million initiative funded by the Bill & Melinda Gates Foundation. Launched in 2008, over 850 people in more than 50 countries have received Grand Challenges Explorations grants. The grant program is open to anyone from any discipline and from any organization. The initiative uses an agile, accelerated grant-making process with short two-page online applications and no preliminary data required. Initial grants of US$100,000 are awarded two times a year. Successful projects have the opportunity to receive a follow-on grant of up to US$1 million.

About Jefferson

Thomas Jefferson University (TJU), the largest freestanding academic medical center in Philadelphia, is nationally renowned for medical and health sciences education and innovative research. Founded in 1824, TJU includes Jefferson Medical College (JMC), one of the largest private medical schools in the country and ranked among the nation's best medical schools by U.S. News & World Report, and the Jefferson Schools of Nursing, Pharmacy, Health Professions, Population Health and the Graduate School of Biomedical Sciences. Jefferson University Physicians is TJU's multi-specialty physician practice consisting of the full-time faculty of JMC. Thomas Jefferson University partners with its clinical affiliate, Thomas Jefferson University Hospitals.

Thomas Jefferson University

Related Vaccine Articles from Brightsurf:

Who should get the COVID-19 vaccine first?
Nineteen global health experts from around the world have proposed a new, three-phase plan for vaccine distribution -- called the Fair Priority Model -- which aims to reduce premature deaths and other irreversible health consequences from COVID-19.

Breakthrough with cancer vaccine
Scientists have developed a new cancer vaccine with the potential to activate the body's immune system to fight a range of cancers, including leukaemia, breast cancer, lung cancer and pancreatic cancers.

How to improve the pneumococcus vaccine
Pneumococcus kills 1 million children annually according to the World Health Organization.

US inroads to better Ebola vaccine
As the world focuses on finding a COVID-19 vaccine, research continues on other potentially catastrophic pandemic diseases, including Ebola and Marburg viruses.

Successful MERS vaccine in mice may hold promise for COVID-19 vaccine
In a new study, published April 7 in mBio, researchers from the University of Iowa and the University of Georgia demonstrate that a new vaccine fully protects mice against a lethal dose of MERS, a close cousin of COVID-19.

Coronavirus Vaccine: Where are we and what's next? (video)
You might have heard that COVID-19 vaccine trials are underway in Seattle.

Why isn't there a vaccine for staph?
A study from Washington University School of Medicine in St.

Exposing vaccine hesitant to real-life pain of diseases makes them more pro-vaccine
New research from Brigham Young University professors finds there is a better way to help increase support for vaccinations: Expose people to the pain and suffering caused by vaccine-preventable diseases instead of trying to combat people with vaccine facts.

Lifetime flu vaccine?
Another year, another flu vaccine because so far scientists haven't managed to make a vaccine that protects against all strains of flu.

On the horizon: An acne vaccine
A new study published in the Journal of Investigative Dermatology reports important steps that have been taken towards the development of an acne vaccine.

Read More: Vaccine News and Vaccine Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.